New Research: Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned survival model#FrontiersIn #Pharmacology
#FrontiersIn #Pharmacology